Zongertinib

from OncoPharm · host John Bossaer

A new ERBB2 (HER2) targeting TKI is approved for NSCLC. We review the characteristics of the drug and summarize the current landscape in treating HER-mutated advanced NSCLC.

Episode metadata supplied by the publisher feed · Published Aug 14, 2025

Embed this episode

Attribution link and audio player

Ready to play

Zongertinib

0:00 12:07

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of OncoPharm?

This episode is 12 minutes long.

When was this OncoPharm episode published?

This episode was published on August 14, 2025.

Can I download this OncoPharm episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!